) The Southern Nevada Cancer Research Foundation (SNCRF) was established to conduct cancer research under the Community Clinical Oncology Program (CCOP) structure. It is a free standing non-hospital based CCOP. The long term objectives have been: 1) To accrue a minimum of 50 credits annually to CCOP approved group treatment clinical trials. 2) To accrue a minimum of 50 credits annually to CCOP approved cooperative group cancer control studies. 3) To provide to the cooperative groups in the NCI timely data of high quality. 4) To promote quality and state of the art treatment in the community through the participation in protocol studies by: (a) Involving all CCOP physicians and staff in scientific and educational activities of the research bases. (b) Expanding the knowledge, awareness and involvement of the primary health care providers and other specialists for the development and use of cancer control research. 5) To actively support other professional educational programs and cancer control outreach services to under-served areas, and to identify women and minority groups that may be under-served and make a special effort to involve them in clinical trials. 6) To actively work with the NCI to develop a community cancer network in order to facilitate the growth and development of important new cancer initiatives. In order to better accomplish all of these goals, the CCOP has expanded to include 50 investigators from varied medical specialties. The family Practice Residency Program and Clinic at the University of Nevada have been added and a third major hospital has been added for participation in the CCOP. This will provide increased access to patients and increase public and medical awareness of the CCOP. The methods for accomplishing these goals will be through the application of CCOP grant money.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA035421-14
Application #
2007418
Study Section
Special Emphasis Panel (ZCA1-RLB-7 (J2))
Project Start
1983-09-30
Project End
2002-05-31
Budget Start
1997-07-15
Budget End
1998-05-31
Support Year
14
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Southern Nevada Cancer Research Fdn
Department
Type
DUNS #
173852054
City
Las Vegas
State
NV
Country
United States
Zip Code
89106
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48

Showing the most recent 10 out of 59 publications